GSK Buys Back Own Shares
Ticker: GLAXF · Form: 6-K · Filed: Apr 15, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Apr 15, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-buyback, stock-transaction
Related Tickers: GSK
TL;DR
GSK is buying back its own stock via Citigroup.
AI Summary
GSK plc announced on April 15, 2025, that it purchased a number of its own ordinary shares through its corporate stockbroker, Citigroup Global Markets Limited. The filing does not specify the exact number of shares or the total dollar amount of the transaction.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — This is a routine disclosure of share repurchases, which is common for publicly traded companies.
Key Players & Entities
- GSK plc (company) — Registrant
- Citigroup Global Markets Limited (company) — Corporate stockbroker
- 31¼ pence (dollar_amount) — Nominal value of ordinary shares
FAQ
What was the specific date of the share purchase?
The filing states the report is for the month of April 2025 and mentions a purchase date, but the exact date is not provided in the excerpt.
How many ordinary shares did GSK plc purchase?
The filing states that a 'number' of ordinary shares were purchased, but the specific quantity is not detailed in the provided text.
What was the total value of the share repurchase program?
The filing does not disclose the total dollar amount of the shares purchased.
Who acted as GSK's corporate stockbroker for this transaction?
Citigroup Global Markets Limited acted as GSK's corporate stockbroker.
What is the nominal value of GSK's ordinary shares?
The nominal value of GSK's ordinary shares is 31¼ pence each.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 15, 2025 regarding GSK plc (GLAXF).